title: Human ex vivo carcinoma cells produce transforming growth factor beta and thereby can inhibit lymphocyte functions in vitro.
abstract: We tested 20 human carcinoma samples for the production of transforming growth factor beta (TGFbeta) in vitro. Tumour cell suspensions without obvious contamination with non-malignant cells were kept in culture conditions for 16 h and their supernatants were added to CCL-64 cells. The proliferation of these cells is inhibited by TGFbeta. According to this assay, the supernatants contained both active and latent TGFbeta. In addition, the supernatants were found to suppress the spontaneous cytotoxic function and activation of T-cell-enriched lymphocyte populations. A specific monoclonal antibody (mAb) counteracted these effects and therefore we concluded that they were mediated to a large extent by TGFbeta. In line with the results obtained with the supernatants, activation of lymphocytes could also be inhibited by tumour cells and their inhibitory effect was weaker in the presence of the TGFbeta-specific mAb. It is important to note that, when TGFbeta-specific mAb was added to autologous mixed lymphocyte/tumour cell cultures, lymphocyte activation occurred more often. These results thus substantiate the assumption that production of TGFbeta may help the survival of potentially immunogenic tumour cells in immunocompetent patients.
authors.affiliation: Microbiology and Tumour Biology Centre, Karolinska Institute, Stockholm, Sweden.
authors.forename: F
authors.initials: F
authors.lastname: Vánky
authors.forename: N
authors.initials: N
authors.lastname: Nagy
authors.forename: C
authors.initials: C
authors.lastname: Hising
authors.forename: K
authors.initials: K
authors.lastname: Sjövall
authors.forename: B
authors.initials: B
authors.lastname: Larson
authors.forename: E
authors.initials: E
authors.lastname: Klein
mesh_terms: D002277:Carcinoma / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology* / Q000473:pathology; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008545:Melanoma / Q000276:immunology* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000473:pathology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D016212:Transforming Growth Factor beta / Q000096:biosynthesis* / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D016212:Transforming Growth Factor beta